US2014296158A1PendingUtilityA1
Sustained action formulation of cyclosporin form 2
Est. expiryNov 15, 2031(~5.3 yrs left)· nominal 20-yr term from priority
A61P 27/02A61P 27/04A61K 47/38A61K 9/0048A61K 38/13C07K 1/306A61K 47/36C07K 7/645A61K 9/0019A61K 47/32A61K 9/10A61K 47/30A61K 9/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A formulation comprising cyclosporin A form 2 and a hydrogel.
2 . The formulation of claim 1 , wherein the hydrogel is selected from hyaluronic acid, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethylcellulose, polyvinyl pyrolidone, carboxymethylcellulose hydroxyethyl cellulose, and polyvinylpyrrolidone.
3 . The formulation of claim 2 , wherein the cyclosporin A form 2 is at a concentration of about 0.01% to about 10%.Join the waitlist — get patent alerts
Track US2014296158A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.